Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)
Status:
Recruiting
Trial end date:
2028-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus
paclitaxel, cisplatin as neoadjuvant therapy followed by surgery, and pembrolizumab as
adjuvant therapy, compared with neoadjuvant chemoradiotherapy and surgery for locally
advanced ESCC in multicenter.
Phase:
Phase 3
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Collaborators:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences Fudan University Harbin Medical University Hebei Medical University Fourth Hospital Liaoning Tumor Hospital & Institute Ruijin Hospital Shandong Jining No.1 People's Hospital Shanghai Chest Hospital Shanghai Zhongshan Hospital Shanxi Province Cancer Hospital Tang-Du Hospital Weifang People's Hospital